Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22314913 | 0.90 | SCN5A (0.48) | SCN5ASCN9AKCNH2SCN1ASCN4A | |
| SCHEMBL22314557 | 0.87 | SCN5A (0.46) | SCN5ASCN9AKCNH2SCN1ASCN4A | |
| SCHEMBL22314549 | 0.83 | CA12 (0.44) | SCN5ASCN9ACA12CA9TNIK | |
| SCHEMBL22314476 | 0.83 | CA12 (0.44) | SCN5ASCN9ACA12CA9TNIK | |
| SCHEMBL22314553 | 0.81 | TNIK (0.51) | CA12CA9TNIKGRIN1GRIN2B | |
| SCHEMBL25865023 | 0.81 | CA12 (0.42) | SCN5ASCN9ACA12CA9TNIK | |
| SCHEMBL22314906 | 0.79 | CA12 (0.46) | SCN5ASCN9ASCN10ACA12CA9 | |
| SCHEMBL22314494 | 0.77 | RAB9A (0.42) | SCN5A | |
| SCHEMBL22314911 | 0.76 | SCN5A (0.52) | SCN5ASCN9AKCNH2SCN1ASCN4A | |
| SCHEMBL22314991 | 0.75 | SCN5A (0.42) | SCN5ASCN9AKCNH2SCN1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885SCN9A 42/4885KCNH2 47/4885 |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885SCN9A 42/4885KCNH2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.